685 related articles for article (PubMed ID: 22814748)
1. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Olson EJ; Pearce GL; Jones NP; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
3. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.
Risérus U; Sprecher D; Johnson T; Olson E; Hirschberg S; Liu A; Fang Z; Hegde P; Richards D; Sarov-Blat L; Strum JC; Basu S; Cheeseman J; Fielding BA; Humphreys SM; Danoff T; Moore NR; Murgatroyd P; O'Rahilly S; Sutton P; Willson T; Hassall D; Frayn KN; Karpe F
Diabetes; 2008 Feb; 57(2):332-9. PubMed ID: 18024853
[TBL] [Abstract][Full Text] [Related]
4. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol.
Savinova OV; Fillaus K; Harris WS; Shearer GC
Atherosclerosis; 2015 Jun; 240(2):520-5. PubMed ID: 25932792
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
[TBL] [Abstract][Full Text] [Related]
6. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.
Chen W; Wang LL; Liu HY; Long L; Li S
Basic Clin Pharmacol Toxicol; 2008 Sep; 103(3):240-6. PubMed ID: 18684227
[TBL] [Abstract][Full Text] [Related]
8. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
10. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
11. Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Choi YJ; Roberts BK; Wang X; Geaney JC; Naim S; Wojnoonski K; Karpf DB; Krauss RM
Atherosclerosis; 2012 Feb; 220(2):470-6. PubMed ID: 22169113
[TBL] [Abstract][Full Text] [Related]
12. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women.
Matthan NR; Welty FK; Barrett PH; Harausz C; Dolnikowski GG; Parks JS; Eckel RH; Schaefer EJ; Lichtenstein AH
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1092-7. PubMed ID: 15087307
[TBL] [Abstract][Full Text] [Related]
13. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
[TBL] [Abstract][Full Text] [Related]
15. Management of non-high-density lipoprotein abnormalities.
Rosenson RS
Atherosclerosis; 2009 Dec; 207(2):328-35. PubMed ID: 19545870
[TBL] [Abstract][Full Text] [Related]
16. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects.
Hughes TA; Stentz F; Gettys T; Smith SR
Metabolism; 2006 Jan; 55(1):26-34. PubMed ID: 16324916
[TBL] [Abstract][Full Text] [Related]
17. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized, controlled trial of the effects of two eggs per day in moderately hypercholesterolemic and combined hyperlipidemic subjects taught the NCEP step I diet.
Knopp RH; Retzlaff BM; Walden CE; Dowdy AA; Tsunehara CH; Austin MA; Nguyen T
J Am Coll Nutr; 1997 Dec; 16(6):551-61. PubMed ID: 9430083
[TBL] [Abstract][Full Text] [Related]
19. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.
Decochez K; Rippley RK; Miller JL; De Smet M; Yan KX; Matthijs Z; Riffel KA; Song H; Zhu H; Maynor HO; Tanaka W; Johnson-Levonas AO; Davies MJ; Gottesdiener KM; Keymeulen B; Wagner JA
Drugs R D; 2006; 7(2):99-110. PubMed ID: 16542056
[TBL] [Abstract][Full Text] [Related]
20. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]